176 related articles for article (PubMed ID: 28190249)
1. Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients.
Lim EA; Gunther JE; Kim HK; Flexman M; Hibshoosh H; Crew K; Taback B; Campbell J; Kalinsky K; Hielscher A; Hershman DL
Breast Cancer Res Treat; 2017 Apr; 162(3):533-540. PubMed ID: 28190249
[TBL] [Abstract][Full Text] [Related]
2. Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy for Breast Cancer.
Cao X; Muller KE; Chamberlin MD; Gui J; Kaufman PA; Schwartz GN; diFlorio-Alexander RM; Pogue BW; Paulsen KD; Jiang S
Clin Cancer Res; 2023 Dec; 29(23):4822-4829. PubMed ID: 37733788
[TBL] [Abstract][Full Text] [Related]
3. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Steenbruggen TG; van Seijen M; Janssen LM; van Ramshorst MS; van Werkhoven E; Vrancken Peeters MTDF; Wesseling J; Lips EH; Sonke GS
Clin Cancer Res; 2019 Aug; 25(16):4985-4992. PubMed ID: 31076546
[TBL] [Abstract][Full Text] [Related]
5. Assessment of residual cancer burden and survival in neoadjuvant chemotherapy of inoperable stage III breast cancer: A ten-year follow-up analysis in Vietnam.
Pham HK; Le TD; Nguyen TP; Le TU; Ta HH; Nguyen VC
Pathol Res Pract; 2024 Feb; 254():155099. PubMed ID: 38244433
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
Takahashi Y; Iwamoto T; Suzuki Y; Kajiwara Y; Hatono M; Tsukioki T; Kawada K; Kochi M; Ikeda H; Shien T; Taira N; Matsuoka J; Doihara H; Toyooka S
Clin Breast Cancer; 2020 Apr; 20(2):117-124.e4. PubMed ID: 31570267
[TBL] [Abstract][Full Text] [Related]
7. Functional hemodynamic imaging markers for the prediction of pathological outcomes in breast cancer patients treated with neoadjuvant chemotherapy.
Deng B; Muldoon A; Cormier J; Mercaldo ND; Niehoff E; Moffett N; Saksena MA; Isakoff SJ; Carp SA
J Biomed Opt; 2024 Jun; 29(6):066001. PubMed ID: 38737790
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
[TBL] [Abstract][Full Text] [Related]
10. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Noda S; Takashima T; Onoda N; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
BMC Cancer; 2017 Dec; 17(1):888. PubMed ID: 29282021
[TBL] [Abstract][Full Text] [Related]
11. The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy.
Xu X; Zhao W; Liu C; Gao Y; Chen D; Wu M; Li C; Wang X; Song X; Yu J; Liu Z; Yu Z
BMC Cancer; 2024 Jan; 24(1):13. PubMed ID: 38166846
[TBL] [Abstract][Full Text] [Related]
12. Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
Ma Y; Zhang S; Zang L; Li J; Li J; Kang Y; Ren W
Eur J Cancer; 2016 Dec; 69():86-101. PubMed ID: 27821323
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
14. Value of ultrasound in assessing response to neoadjuvant chemotherapy in breast cancer.
Lim HF; Sharma A; Gallagher C; Hall P
Clin Radiol; 2023 Dec; 78(12):912-918. PubMed ID: 37734976
[TBL] [Abstract][Full Text] [Related]
15. Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer.
Peintinger F; Anderson K; Mazouni C; Kuerer HM; Hatzis C; Lin F; Hortobagyi GN; Symmans WF; Pusztai L
Clin Cancer Res; 2007 Jul; 13(14):4078-82. PubMed ID: 17634532
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
Hylton NM; Gatsonis CA; Rosen MA; Lehman CD; Newitt DC; Partridge SC; Bernreuter WK; Pisano ED; Morris EA; Weatherall PT; Polin SM; Newstead GM; Marques HS; Esserman LJ; Schnall MD;
Radiology; 2016 Apr; 279(1):44-55. PubMed ID: 26624971
[TBL] [Abstract][Full Text] [Related]
17. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer.
Cockburn A; Yan J; Rahardja D; Euhus D; Peng Y; Fang Y; Rumnong Sarode V
Hum Pathol; 2014 Feb; 45(2):249-58. PubMed ID: 24289969
[TBL] [Abstract][Full Text] [Related]
18. Optical Mammography in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: Individual Clinical Response Index.
Anderson PG; Kalli S; Sassaroli A; Krishnamurthy N; Makim SS; Graham RA; Fantini S
Acad Radiol; 2017 Oct; 24(10):1240-1255. PubMed ID: 28532642
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
[TBL] [Abstract][Full Text] [Related]
20. Validation of the Residual Cancer Burden Index as a prognostic tool in women with locally advanced breast cancer treated with neoadjuvant chemotherapy.
Gomes da Cunha JP; Goncalves R; Silva F; Aguiar FN; Mota BS; Chequim BB; Soares JM; Baracat EC; Filassi JR
J Clin Pathol; 2023 Apr; 76(4):239-243. PubMed ID: 34620608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
